Close

Aegis Affirms 'Buy' Rating on Sciclone (SCLN); Comments on Registration Approval of DC Bead in China

August 29, 2014 9:30 AM EDT Send to a Friend
Aegis Capial affirms Sciclone Pharma (Nasdaq: SCLN) at Buy with a target price of $8 following news Thursday morning that ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login